CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zalicus Inc. (NASDAQ: ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases announced that Zalicus management will provide an overview of the Company at two upcoming investor conferences:
